Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities
about
The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert CommentaryManagement strategies in the treatment of neonatal and pediatric gastroenteritisAt the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancerA review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication.Pathogenesis and risk factors for gastric cancer after Helicobacter pylori eradicationReinfection after successful eradication of Helicobacter pylori in three different populations in Alaska.Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer preventionEffects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroupsManagement of Helicobacter pylori infection in Latin America: a Delphi technique-based consensusEarly or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model.Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: a systematic review.Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase.Epidemiology of Helicobacter pylori infection in dyspeptic Ghanaian patientsThe Globalization of Cooperative Groups.Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy.Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention.Unintended consequences of Helicobacter pylori infection in children in developing countries: iron deficiency, diarrhea, and growth retardation.Biomarkers of Helicobacter pylori-associated gastric cancer.Helicobacter pylori: evidence-based review with a focus on immigrant populations.Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, PeruDiagnosis and epidemiology of Helicobacter pylori infection.Treatment of Helicobacter pylori infection 2013.Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori.Polyamine- and NADPH-dependent generation of ROS during Helicobacter pylori infection: A blessing in disguise.Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis.Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomesSystematic review with meta-analysis: the global recurrence rate of Helicobacter pylori.Helicobacter pylori recurrence after first- and second-line eradication therapy in Korea: the problem of recrudescence or reinfection.Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis.Recurrence of Helicobacter pylori infection in Bolivian children and adults after a population-based "screen and treat" strategy.Epidemiology of Helicobacter pylori infection
P2860
Q26852409-7B123FBF-E372-4186-832F-BB85ECAA5D4FQ27004496-905F03E5-0688-4BD4-81E4-0FA0B4A7B532Q27023485-207D6CB4-4FA3-41E1-9146-FCD2E33F8BAFQ27687842-A9C44722-E864-43BE-BDE3-595DFAE91DF3Q28074674-1A18D8D4-1BB4-4DF6-8A13-B32F833D83F1Q30209223-AE5E50F2-A743-4696-8360-D0A3F2507382Q33560119-6A9A12AF-C168-4C9E-A03D-509F22EDA99CQ33792622-20DB8076-DCE1-4A2D-A7E0-9E97D56CEC90Q34067951-BD68D91E-F2E6-4DD3-A245-1E567E8ED16CQ34339051-7DF7F284-54A3-4D0C-884C-C157E562FF96Q34404967-061EC22E-4EBD-45ED-BB5F-BCB145083808Q35133419-1D8D49CB-B37E-48F7-856C-FC5BFA9D799EQ36080429-D0BF00B2-E9C3-4A05-B9AC-2A878BA24384Q36119749-9B7E7AB1-B02A-4010-8102-F48E9C700282Q36549258-E616C7D3-61BB-4AF3-802B-FE25360E9057Q37433766-5F409CFB-958E-4F39-B1C8-9018A70C6F24Q37591503-DB007AFA-9A1F-4B77-BDB5-5B5E246A0D0EQ37591506-54395AD3-1527-40FE-8380-399E6AD1D35EQ37595765-8CA7A922-26F1-46A2-8F78-EE65DD8153E7Q37705632-D328A092-2EFA-4D80-8A61-35DECA753402Q38134864-D219EDEC-8891-40BE-AA82-E734B552AE73Q38134877-9D1DEA0D-B2FC-4D1B-8826-F9D91718C0BCQ38191566-525A0CDA-A4E6-46CC-8283-3782654D9F80Q38496942-5D46ABA3-A1C3-4726-9766-B6FE36966114Q38967255-4E5CEE66-44E5-4962-BB1B-C87E0605E320Q40225793-31B7D6FC-833F-416E-B414-BAE58E244CB5Q41109955-B21C60D4-0779-4391-A664-8B928E1F3DDAQ43365053-FBAE37AE-EC3D-463D-BFE5-D5610A02BFACQ44714287-48026683-7596-4D7C-BBDF-DBCCB211376DQ48225195-C1A22790-C519-4045-9AA2-AFF39C413B98Q51246901-384719FF-3ACD-439B-BBFD-625C17FE2A3AQ56973079-D25AE797-0B0E-40F8-ADF0-B2019CEB0179
P2860
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Risk of recurrent Helicobacter ...... n 7 Latin American communities
@en
type
label
Risk of recurrent Helicobacter ...... n 7 Latin American communities
@en
prefLabel
Risk of recurrent Helicobacter ...... n 7 Latin American communities
@en
P2093
P2860
P50
P356
P1476
Risk of recurrent Helicobacter ...... n 7 Latin American communities
@en
P2093
Douglas R Morgan
E Robert Greenberg
Edgar M Peña
Eduardo C Lazcano-Ponce
Eduardo Salazar-Martínez
Gary E Goodman
Javier Torres
John J Crowley
Laurence H Baker
Manuel Valdivieso
P2860
P304
P356
10.1001/JAMA.2013.311
P407
P577
2013-02-01T00:00:00Z